The Aquila study demonstrates a significant progression-free survival benefit by treating high-risk smoldering myeloma with daratumumab instead of the traditional "watch and wait" approach. This marks a major paradigm shift toward early intervention for this precursor condition, with emerging data also suggesting a potential overall survival benefit.
The IMRAZ study found that patients treated with the Isa-VRD quadruplet who converted from MRD-negative to MRD-positive still had better outcomes than those on the VRD triplet. This suggests the four-drug regimen provides a deeper response or a lasting favorable impact on the tumor microenvironment beyond just achieving initial MRD negativity.
The Benefit study challenged the need for bortezomib in a modern quadruplet regimen. It found that adding bortezomib to an isatuximab-lenalidomide-dexamethasone backbone significantly improved response rates and sustained MRD negativity, confirming the proteasome inhibitor's ongoing, critical role even when using powerful new agents.
The Araclia study showed subcutaneous isatuximab via an on-body injector had identical efficacy to its IV formulation. The key differentiator was user experience; surveys revealed that both patients and nurses were significantly happier with the subcutaneous method. This highlights that convenience and quality of life are crucial for drug adoption.
New cereblon modulating agents (CELMoDs) like mezigdemide are showing significant efficacy in patients refractory to lenalidomide and anti-CD38 antibodies. The Successor-2 trial demonstrated a dramatic progression-free survival benefit, highlighting a new therapeutic avenue for a difficult-to-treat patient population by overcoming prior treatment resistance.